ARIP2B Antibody FITC Conjugated

Catalog No: #C00449F

Description



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Decemption	
Product Name	ARIP2B Antibody FITC Conjugated
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Purified by Protein A.
Applications	IF
Species Reactivity	Ms Rt
Immunogen Description	KLH conjugated synthetic peptide aa 300-350 512 derived from rat ARIP2B
Conjugates	FITC
Target Name	ARIP2B
Other Names	Activin receptor type-2B; Activin receptor type IIB; ACTR-IIB; Acvr2b; Actriib
Accession No.	Swiss-Prot#P38445NCBI Gene ID25366
Uniprot	P38445
GeneID	25366;
Excitation Emission	494nm 518nm
Cell Localization	Cytoplasm
Concentration	1mg ml
Formulation	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Application Details

IF=1:50-200

Background

Transmembrane serine threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A INHBA, activin-B INHBB as well as inhibin-A INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor (By similarity).

Note: This product is for in vitro research use only